Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.

Fredrika KoskimäkiJacqueline BernardYong Ik JeongNancy ArndtTimothy CarrollSeon-Kyu LeeAnthony T RederAdil Javed

Published in: PloS one (2018)

These results demonstrate that brain volume loss in MS is primarily driven by gray matter changes and may be independent of clinically effective treatment.

Keyphrases

multiple sclerosis
white matter
mass spectrometry
ms ms
combination therapy
brain injury